Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | RHEB | Q15382 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333939 | 0.84 | EGFR (0.39) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL2261309 | 0.84 | SLC6A4 (0.48) | SLC6A4HTR2AKCNH2RHEBSLC6A2 | |
| SCHEMBL693499 | 0.84 | SLC6A4 (0.48) | SLC6A4HTR2AKCNH2RHEBSLC6A2 | |
| SCHEMBL231083 | 0.82 | DPP4 (0.43) | SLC6A4HTR2AMRGPRX4LMNAL3MBTL1 | |
| SCHEMBL9686248 | 0.81 | SLC6A4 (0.44) | SLC6A4HTR2AKCNH2RHEBSLC6A2 | |
| SCHEMBL985888 | 0.80 | EGFR (0.44) | MRGPRX4EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL984918 | 0.80 | STK39 (0.44) | SLC6A4HTR2AKCNH2L3MBTL1EGFR | |
| SCHEMBL1375267 | 0.79 | MAPT (0.42) | SLC6A4HTR2AKCNH2RHEBSLC6A2 | |
| SCHEMBL2329133 | 0.77 | TTR (0.55) | SLC6A4KCNH2RHEBSLC6A2SLC6A3 | |
| SCHEMBL919571 | 0.77 | AR (0.44) | SLC6A4HTR2AKCNH2RHEBSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1134439-C | Pyrrolo [2,3D ] pyrimidines and their use as tyrosine kinase inhibitors | 艾博特股份有限两合公司 | 2004-01-14 | — | — | CN | claimed |
| EP-0970084-B1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AG (DE) | 2003-06-04 | — | — | EP | claimed |
| CN-1259950-A | Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors | BASF AG (DE) | 2000-07-12 | — | — | CN | claimed |
| EP-0970084-A1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-12 | — | — | EP | claimed |
| US-6001839-A | Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-14 | — | — | US | claimed |
| WO-1998041525-A1 | PYRROLO[2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | claimed |
| EP-2359825-A2 | Combination drug | Takeda Pharmaceutical Company Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-20110003805-A1 | CONCOMITANT DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255830-A1 | CONCOMITANT DRUG | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7825127-B2 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20100008912-A1 | COMBINATION DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-14 | — | — | US | disclosed |
| CN-101553222-A | Combination drug | TAKEDA PHARMACEUTICAL (JP) | 2009-10-07 | — | — | CN | disclosed |
| EP-2063895-A2 | COMBINATION DRUG | Takeda Pharmaceutical Company Limited (JP) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008044782-A2 | COMBINATION DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-04-17 | — | — | WO | disclosed |
| CN-1134439-C | Pyrrolo [2,3D ] pyrimidines and their use as tyrosine kinase inhibitors | 艾博特股份有限两合公司 | 2004-01-14 | — | — | CN | disclosed |
| EP-0970084-B1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AG (DE) | 2003-06-04 | — | — | EP | disclosed |
| CN-1259950-A | Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors | BASF AG (DE) | 2000-07-12 | — | — | CN | disclosed |
| EP-0970084-A1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-12 | — | — | EP | disclosed |
| US-6001839-A | Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-14 | — | — | US | disclosed |
| WO-1998041525-A1 | PYRROLO[2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008912-A1 | COMBINATION DRUG | ERBB2, ERBB3, ERBB4 | SLC6A4 2018/4885HTR2A 965/4885KCNH2 4653/4885 |
| US-20110003805-A1 | CONCOMITANT DRUG | ERBB2, MTOR, ERBB4 | SLC6A4 640/4885HTR2A 819/4885KCNH2 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.